Stock FHTX FOGHORN THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Foghorn Therapeutics Inc.

Equities

FHTX

US3441741077

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-05-03 EDT 		5-day change 1st Jan Change
5.99 USD -1.96% Intraday chart for Foghorn Therapeutics Inc. +9.11% -7.13%
04-16 Foghorn Therapeutics Names Kristian Humer CFO MT
04-16 Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Foghorn Therapeutics Names Kristian Humer CFO
MT
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
GL
Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer
CI
Transcript : Foghorn Therapeutics Inc. - Special Call
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
GL
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
AQ
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
GL
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
GL
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
GL
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
AQ
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
GL
Foghorn Therapeutics Inc. to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909
CI
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
GL
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
AQ
Eli Lilly: Foghorn's anti-tumor drug selected for clinical development
CF
Foghorn Shares Rally as Eli Lilly Plans Clinical Program With Oncology Product
DJ
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
GL
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
CI
Foghorn Therapeutics Inc. Appoints Stephen J. Dipalma Interim Chief Financial Officer, Effective January 16, 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FHTX Stock
  4. News Foghorn Therapeutics Inc.